What's Happening?
Vanda Pharmaceuticals has initiated the Thetis study, a clinical trial evaluating NEREUS™ (tradipitant) for preventing vomiting in patients using GLP-1 receptor agonists. These therapies, used for type 2 diabetes and obesity, often cause gastrointestinal
side effects like nausea and vomiting, leading to treatment discontinuation. The trial aims to assess the efficacy of tradipitant in reducing these side effects, potentially improving patient adherence and quality of life. The study is a multicenter, randomized, double-blind, placebo-controlled trial, with results expected by Q4 2026.
Why It's Important?
The trial addresses a significant barrier in the treatment of diabetes and obesity, where side effects from GLP-1 receptor agonists can limit their effectiveness. By potentially reducing these adverse effects, the study could enhance patient adherence to these therapies, maximizing their benefits. This development is crucial for patients who struggle with the side effects of current treatments, offering a pathway to improved health outcomes and quality of life.
What's Next?
Vanda Pharmaceuticals anticipates topline results from the Thetis study by the end of 2026. Depending on the outcomes, further data may be required before a New Drug Application can be approved. The success of this trial could lead to broader applications of NEREUS™ in managing side effects of GLP-1 therapies, potentially transforming treatment protocols for diabetes and obesity.
